Millions of babies and children undergo anaesthesia every year. Preclinical evidence shows that all common anaesthetic drugs are associated with neuro-apoptosis and neurodevelopmental deficits in immature rodent models. Xenon, a low-potency anaesthetic gas, renowned for producing cardiostable anaesthesia and with neuroprotective properties in multiple pathologies, was recently used to reduce sevoflurane requirements of babies and young children undergoing cardiac catheterisation. Preclinical studies have shown the addition of xenon reduced neuroapoptosis induced by 0.7% isoflurane in vivo and in vitro.
Recent Posts
- SmartTots and the Power of Scientific Public–Private Partnerships with the US Food and Drug Administration
- Effects of Dexmedetomidine-Remifentanil on Neurodevelopment of Children after Inhalation Anesthesia: A Randomized Clinical Trial
- A Scoping Review of the Mechanisms Underlying Developmental Anesthetic Neurotoxicity
- Anesthesia-induced Developmental Neurotoxicity in Pediatric Population
- Experiencing Anesthesia and Surgery Early in Life Impairs Cognitive and Behavioral Development